Millennium Capital Advisors’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$4.35M Sell
3,623
-44
-1% -$45K 2.37% 9
2026
Q1
$3.37M Buy
3,667
+1
+0% +$1.01K 2.08% 10
2025
Q4
$3.94M Sell
3,666
-12
-0.3% -$11.5K 2.32% 9
2025
Q3
$2.81M Sell
3,678
-111
-3% -$82.6K 1.69% 12
2025
Q2
$2.95M Buy
3,789
+91
+2% +$70.7K 1.97% 9
2025
Q1
$3.05M Sell
3,698
-200
-5% -$166K 2.25% 7
2024
Q4
$3.01M Buy
3,898
+55
+1% +$45.5K 2.05% 9
2024
Q3
$3.4M Buy
3,843
+53
+1% +$47.6K 2.22% 9
2024
Q2
$3.43M Buy
3,790
+9
+0.2% +$7.2K 2.28% 9
2024
Q1
$2.94M Buy
3,781
+22
+0.6% +$15.7K 2.08% 9
2023
Q4
$2.19M Sell
3,759
-9
-0.2% -$5.25K 1.68% 13
2023
Q3
$2.02M Sell
3,768
-43
-1% -$22.2K 1.73% 14
2023
Q2
$1.79M Sell
3,811
-156
-4% -$65.4K 1.47% 17
2023
Q1
$1.36M Buy
3,967
+36
+0.9% +$12.1K 1.22% 19
2022
Q4
$1.44M Buy
3,931
+163
+4% +$57.8K 1.45% 17
2022
Q3
$1.22M Buy
3,768
+80
+2% +$25.3K 1.29% 18
2022
Q2
$1.2M Buy
3,688
+254
+7% +$76.2K 1.17% 19
2022
Q1
$983K Buy
3,434
+308
+10% +$79.3K 0.79% 32
2021
Q4
$863K Buy
+3,126
New +$792K 0.67% 36

Other funds holding LLY

Millennium Capital Advisors's LLY Position: Q2 2026 in Review

Millennium Capital Advisors reduced its Eli Lilly (LLY) stake by 1.2% in Q2 2026, selling an estimated $45K and leaving 3,623 shares worth $4.35M. The position accounts for 2.37% of the portfolio, ranked #9.

Millennium Capital Advisors first reported a position in LLY in Q4 2021 and has held it in 19 quarters since. 4,607 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

  • Millennium Capital Advisors held 3,623 shares of Eli Lilly worth $4.35M as of Q2 2026.
  • Millennium Capital Advisors sold 44 Eli Lilly shares in Q2 2026, an estimated $45K.
  • Eli Lilly made up 2.37% of Millennium Capital Advisors's portfolio in Q2 2026, its #9 holding.
  • Millennium Capital Advisors first reported a position in Eli Lilly in Q4 2021 and has held it in 19 quarters since.
  • 4,607 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on Millennium Capital Advisors's 13F filing for Q2 2026, filed 28 Jul 2026.